In-Vitro Sorbent-Mediated Removal of Edoxaban from Human Plasma and Albumin Solution.
Journal
Drugs in R&D
ISSN: 1179-6901
Titre abrégé: Drugs R D
Pays: New Zealand
ID NLM: 100883647
Informations de publication
Date de publication:
Sep 2020
Sep 2020
Historique:
pubmed:
18
5
2020
medline:
4
2
2021
entrez:
17
5
2020
Statut:
ppublish
Résumé
Based on previous experience of sorbent-mediated ticagrelor, dabigatran, and radiocontrast agent removal, we set out in this study to test the effect of two sorbents on the removal of edoxaban, a factor Xa antagonist direct oral anticoagulant. We circulated 100 mL of edoxaban solution during six first-pass cycles through 40-mL sorbent columns (containing either CytoSorb in three passes or Porapak Q 50-80 mesh in the remaining three passes) during experiments using human plasma and 4% bovine serum albumin solution as drug vehicles. Drug concentration was measured by liquid chromatography-tandem mass spectrometry. Edoxaban concentration in two experiments performed with human plasma dropped from 276.8 to 2.7 ng/mL and undetectable concentrations, respectively, with CytoSorb or Porapak Q 50-80 mesh (p = 0.0031). The average edoxaban concentration decreased from 407 ng/mL ± 216 ng/mL to 3.3 ng/mL ± 7 ng/mL (p = 0.017), for a removal rate of 99% across all six samples of human plasma (two samples) and bovine serum albumin solution (four samples). In four out of the six adsorbed samples, the drug concentrations were undetectable. Sorbent-mediated technology may represent a viable pathway for edoxaban removal from human plasma or albumin solution.
Sections du résumé
BACKGROUND AND OBJECTIVE
OBJECTIVE
Based on previous experience of sorbent-mediated ticagrelor, dabigatran, and radiocontrast agent removal, we set out in this study to test the effect of two sorbents on the removal of edoxaban, a factor Xa antagonist direct oral anticoagulant.
METHODS
METHODS
We circulated 100 mL of edoxaban solution during six first-pass cycles through 40-mL sorbent columns (containing either CytoSorb in three passes or Porapak Q 50-80 mesh in the remaining three passes) during experiments using human plasma and 4% bovine serum albumin solution as drug vehicles. Drug concentration was measured by liquid chromatography-tandem mass spectrometry.
RESULTS
RESULTS
Edoxaban concentration in two experiments performed with human plasma dropped from 276.8 to 2.7 ng/mL and undetectable concentrations, respectively, with CytoSorb or Porapak Q 50-80 mesh (p = 0.0031). The average edoxaban concentration decreased from 407 ng/mL ± 216 ng/mL to 3.3 ng/mL ± 7 ng/mL (p = 0.017), for a removal rate of 99% across all six samples of human plasma (two samples) and bovine serum albumin solution (four samples). In four out of the six adsorbed samples, the drug concentrations were undetectable.
CONCLUSION
CONCLUSIONS
Sorbent-mediated technology may represent a viable pathway for edoxaban removal from human plasma or albumin solution.
Identifiants
pubmed: 32415538
doi: 10.1007/s40268-020-00308-1
pii: 10.1007/s40268-020-00308-1
pmc: PMC7419416
doi:
Substances chimiques
Albumins
0
Factor Xa Inhibitors
0
Pyridines
0
Styrenes
0
Thiazoles
0
edoxaban
NDU3J18APO
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
217-223Références
Lancet. 2015 Jun 6;385(9984):2288-95
pubmed: 25769361
Thromb Haemost. 2013 Apr;109(4):596-605
pubmed: 23389759
JACC Basic Transl Sci. 2017 Apr 24;2(2):135-145
pubmed: 30167561
J Chromatogr A. 1997 Feb 21;762(1-2):235-41
pubmed: 9098982
Ther Adv Drug Saf. 2019 Nov 26;10:2042098619888133
pubmed: 31807265
Thromb Haemost. 2015 Apr;113(4):719-27
pubmed: 25566930
N Engl J Med. 2013 Oct 10;369(15):1406-15
pubmed: 23991658
Ann Thorac Surg. 2019 Jul;108(1):45-51
pubmed: 30684482
N Engl J Med. 2013 Nov 28;369(22):2093-104
pubmed: 24251359
Cardiovasc Revasc Med. 2013 Jul-Aug;14(4):207-12
pubmed: 23665118
Int J Cardiol. 2019 Oct 15;293:73-75
pubmed: 31296393
Blood Purif. 2012;34(1):34-9
pubmed: 22907199
Crit Care. 2016 Apr 09;20:96
pubmed: 27059056
Am J Cardiol. 2017 Dec 1;120(11):1961-1965
pubmed: 29033050
Clin Pharmacokinet. 2016 Jun;55(6):641-55
pubmed: 26620048
N Engl J Med. 2016 Sep 22;375(12):1131-41
pubmed: 27573206